Autistic Disorder Pipeline

DelveInsight’s, “Autistic Disorder Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Autistic Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage
  

Autistic Disorder Disease Understanding

Autistic Disorder Overview

Autistic Disorder is a neurodevelopmental condition marked by challenges in social communication, along with restricted interests and repetitive behaviors. Rising prevalence rates have drawn attention to factors influencing diagnosis, including evolving diagnostic criteria. Research suggests that ASD arises from a combination of genetic and environmental influences affecting early brain development. Clinical evaluation typically starts with developmental screening, followed by specialized assessment for a confirmed diagnosis, along with screening for associated coexisting conditions.

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition influenced by a combination of genetic and environmental factors that affect early brain development. Research indicates that variations in brain structure, neural connectivity, and synaptic functioning may contribute to ASD, while genetic studies have identified numerous susceptibility genes linked to brain development, neurotransmission, and neuronal regulation. Environmental factors such as advanced parental age, prenatal exposure to certain medications, maternal infections or immune conditions during pregnancy, prematurity, and certain birth-related complications may also increase risk in genetically susceptible individuals. However, ASD remains highly heterogeneous, with no single definitive cause identified. Importantly, extensive scientific evidence has confirmed that vaccines, including the MMR vaccine, are not associated with ASD.

Evaluation of Autism Spectrum Disorder (ASD) begins with developmental and autism-specific screening during early childhood to identify children at risk, followed by a comprehensive diagnostic assessment if concerns arise. Early signs may include poor eye contact, delayed language or social skills, limited gestures, rigid behaviors, or difficulties with social interaction and communication. Children suspected of having ASD are referred for early intervention, educational support, and specialist evaluation by professionals such as developmental pediatricians, neurologists, psychologists, or psychiatrists. Diagnosis is based on clinical assessment, including developmental history, behavioral observation, physical and neurological examination, and evaluation of cognitive, language, and adaptive functioning, as no definitive biomarker currently exists. Clinicians also assess for commonly associated conditions such as intellectual disability, ADHD, anxiety, epilepsy, gastrointestinal and sleep disorders, obesity, and mood or behavioral problems. Genetic testing, including chromosomal microarray and other targeted analyses, is recommended to identify underlying genetic factors and guide management, while additional laboratory tests, neuroimaging, or EEG are performed only when specific clinical indications or risk factors are present.

Management of Autism Spectrum Disorder (ASD) involves a range of individualized interventions aimed at improving communication, social interaction, adaptive functioning, and overall quality of life. Early intervention is considered essential, with active involvement of families, educators, and healthcare professionals. Evidence-based behavioral and educational therapies, particularly Applied Behavior Analysis (ABA), TEACCH, and developmental models such as the Early Start Denver Model (ESDM), DIR/Floortime, and Relationship Development Intervention (RDI), are widely used to enhance language, cognitive, emotional, and social skills through structured, play-based, and child-centered approaches. Additional supportive interventions, including PECS, Positive Behavior Support, sensory integration, music, exercise, and animal-assisted therapies, may benefit some individuals, although evidence for several remains limited. Pharmacological treatment primarily targets associated symptoms and coexisting conditions such as irritability, seizures, sleep disturbances, anxiety, mood disorders, and gastrointestinal issues, with medications like risperidone, aripiprazole, melatonin, and anticonvulsants commonly used. Dietary and alternative therapies have shown mixed or limited effectiveness, while emerging experimental treatments targeting neurobiological pathways continue to be investigated as potential future therapies for ASD.

"Autistic Disorder Pipeline Insight 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Autistic Disorder pipeline landscape is provided which includes the disease overview and Autistic Disorder treatment guidelines. The assessment part of the report embraces, in depth Autistic Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autistic Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Autistic Disorder Pipeline Report Highlights

• The Autistic Disorder Pipeline companies and academics are working to assess challenges and seek opportunities that could influence Autistic Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Autistic Disorder.
  

Autistic Disorder Emerging Drugs Analysis

This segment of the Autistic Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Autistic Disorder Emerging Drugs

Cariprazine: Abbvie / Gedeon Ritchers

Cariprazine is an atypical antipsychotic that is being developed by Abbvie. It is thought to be effective due to its partial agonist activity at the dopamine D2 receptor and serotonin 5HT1A receptor and its antagonism at the serotonin 5HT2A receptor. Additionally, cariprazine has a high affinity for dopamine D3 receptors, acting as a partial agonist at D3 receptors. Cariprazine is primarily metabolized by CYP3A4 into Desmethyl Cariprazine (DCAR), and DCAR is then further metabolized by CYP3A4 into Didesmethyl Cariprazine (DDCAR). DCAR and DDCAR both display similar pharmacological potencies as cariprazine. Currently, the drug is in the Phase III stage of its development for the treatment of Autistic Disorder.

ML-004: MapLight Therapeutics

MapLight Therapeutics’s ML-004 is an investigational drug for Autism Spectrum Disorder (ASD) being studied to improve core symptoms such as social communication difficulties and irritability. It is a modified formulation of zolmitriptan that targets serotonin 5-HT1B/1D receptors to potentially enhance social behavior and emotional regulation. ML-004 is currently in Phase II clinical trials and has shown acceptable tolerability in early studies, but its safety and effectiveness for ASD are still being evaluated, and it is not yet approved for clinical use.

ARD-501: Aardvark Therapeutics/ Tulex

ART-501, previously referred to as ARD-501 and TLX-032 for Tulex, is a proprietary oral liquid extended-release formulation of a well-established and generally well-tolerated opioid receptor–modulating therapy. The product is being developed through a strategic collaboration between Tulex and Artisan, combining the expertise of both organizations to advance an innovative formulation designed to enhance therapeutic delivery, patient convenience, and overall treatment experience. Currently, the drug is in Phase II stage of its development for the treatment of Autistic Disorder.

SFX-01: STALICLA

STALICLA’s SFX-01 is an investigational oral therapy being developed for a specific biologically defined subgroup of patients with Autism Spectrum Disorder (ASD). It is a patented formulation of synthetic sulforaphane designed to improve stability and bioavailability, with the aim of addressing behavioral and social symptoms associated with autism through a precision medicine approach. SFX-01 remains in clinical development and is not yet approved for ASD treatment. Currently, the drug is in Phase I stage of its development for the treatment of Autistic Disorder.

Further product details are provided in the report……..

Autistic Disorder Drug Therapeutic Assessment

This segment of the report provides insights about the different Autistic Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Autistic Disorder Players in Autistic Disorder  

• There are approx. 20+ key companies which are developing the therapies for Autistic Disorder. The companies which have their Autistic Disorder drug candidates in the most advanced stage, i.e. Phase III include, Abbvie / Gedeon Ritchers.
  

Autistic Disorder Clinical Trial Phases

• DelveInsight’s report covers around 25+ products under different phases of clinical development like
  
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
    

Autistic Disorder Drug Route of Administration

• Autistic Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 
  
  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral 
  • Topical
    

Autistic Disorder Product Molecule Type

• Products have been categorized under various Molecule types such as
  
  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer 
  • Gene therapy

Autistic Disorder Product Type

• Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Autistic Disorder Clinical Trial Activities

The Autistic Disorder Pipeline report provides insights into Autistic Disorder Clinical Trials within Phase III, II, I, preclinical and discovery stage. It also analyses Autistic Disorder therapeutic drugs key players involved in developing key drugs.

Autistic Disorder Pipeline Development Activities

The Autistic Disorder Clinical Trial report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Autistic Disorder drugs.

Autistic Disorder Pipeline Report Insights

• Autistic Disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
  

Autistic Disorder Pipeline Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered In The Autistic Disorder Pipeline Report

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Autistic Disorder drugs?
• How many Autistic Disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Autistic Disorder?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Autistic Disorder therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Autistic Disorder and their status?
•  What are the key designations that have been granted to the emerging drugs?

Autistic Disorder Key Companies

• AbbVie
• Gedeon Richter Plc
• MapLight Therapeutics
• Aardvark Therapeutics
• Tulex
• STALICLA
• Novartis
• Curemark
• Bristol Meyer Squibb
• Brainstorm Cell Therapeutics
• Definium Therapeutics
• Tonix Pharmaceuticals
• Iama Therapeutics
• GBAT Therapeutics
• CONNECTA Therapeutics
• Praxis Precision Medicines
• Neurium Therapeutics
  

Autistic Disorder Key Products

• Cariprazine
• ML-004
• ARD-501
• SFX-01
• STP-7
• CM-AT
• COBENFY
• MSC-NTF Cellular Therapy
• DT402
• TNX-1900
• Lead Program: IAMA-6
• MTT Program: ASD
• CTH120
• PRAX-100
• Neu-6142